AR119198A1 - Proceso para la preparación de inhibidores del canal de cloruro cic-1 - Google Patents
Proceso para la preparación de inhibidores del canal de cloruro cic-1Info
- Publication number
- AR119198A1 AR119198A1 ARP200101735A ARP200101735A AR119198A1 AR 119198 A1 AR119198 A1 AR 119198A1 AR P200101735 A ARP200101735 A AR P200101735A AR P200101735 A ARP200101735 A AR P200101735A AR 119198 A1 AR119198 A1 AR 119198A1
- Authority
- AR
- Argentina
- Prior art keywords
- substituents
- optionally substituted
- different
- group
- alkyl
- Prior art date
Links
- 238000000034 method Methods 0.000 title abstract 2
- 108010062745 Chloride Channels Proteins 0.000 title 1
- 102000011045 Chloride Channels Human genes 0.000 title 1
- 101150052500 cic-1 gene Proteins 0.000 title 1
- 239000003112 inhibitor Substances 0.000 title 1
- 125000001424 substituent group Chemical group 0.000 abstract 10
- YZCKVEUIGOORGS-OUBTZVSYSA-N Deuterium Chemical group [2H] YZCKVEUIGOORGS-OUBTZVSYSA-N 0.000 abstract 6
- 229910052805 deuterium Inorganic materials 0.000 abstract 6
- 125000006555 (C3-C5) cycloalkyl group Chemical group 0.000 abstract 4
- 125000000217 alkyl group Chemical group 0.000 abstract 4
- 125000006273 (C1-C3) alkyl group Chemical group 0.000 abstract 3
- 150000001875 compounds Chemical class 0.000 abstract 3
- 229910052739 hydrogen Inorganic materials 0.000 abstract 3
- 125000003342 alkenyl group Chemical group 0.000 abstract 2
- 125000000304 alkynyl group Chemical group 0.000 abstract 2
- 125000005913 (C3-C6) cycloalkyl group Chemical group 0.000 abstract 1
- XFXPMWWXUTWYJX-UHFFFAOYSA-N Cyanide Chemical group N#[C-] XFXPMWWXUTWYJX-UHFFFAOYSA-N 0.000 abstract 1
- YZCKVEUIGOORGS-NJFSPNSNSA-N Tritium Chemical group [3H] YZCKVEUIGOORGS-NJFSPNSNSA-N 0.000 abstract 1
- 239000002253 acid Substances 0.000 abstract 1
- 125000001797 benzyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])* 0.000 abstract 1
- 125000004093 cyano group Chemical group *C#N 0.000 abstract 1
- 125000000392 cycloalkenyl group Chemical group 0.000 abstract 1
- 125000000956 methoxy group Chemical group [H]C([H])([H])O* 0.000 abstract 1
- 125000000449 nitro group Chemical group [O-][N+](*)=O 0.000 abstract 1
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 abstract 1
- 239000011541 reaction mixture Substances 0.000 abstract 1
- 125000000547 substituted alkyl group Chemical group 0.000 abstract 1
- 229910052722 tritium Inorganic materials 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D261/00—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings
- C07D261/02—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings not condensed with other rings
- C07D261/06—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings not condensed with other rings having two or more double bonds between ring members or between ring members and non-ring members
- C07D261/08—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings not condensed with other rings having two or more double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/42—Oxazoles
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Epidemiology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
Abstract
Reivindicación 1: Un proceso para la preparación de compuestos de la fórmula (1) que comprende la etapa a) en donde i) se hace reaccionar un compuesto de la fórmula (2) con un ácido o una base y ii) se aísla un compuesto de la fórmula (1) a partir de la mezcla de reacción, en donde R¹ es seleccionado del grupo que consiste en H, F, Cl, Br y I; R² es seleccionado del grupo que consiste en C₁₋₅ alquilo y C₃₋₅ cicloalquilo; R³ es seleccionado del grupo que consiste en deuterio, F, Cl, Br y I; R⁴ es seleccionado del grupo que consiste en H, deuterio, C₁₋₅ alquilo, C₂₋₅ alquenilo, C₂₋₅ alquinilo, C₃₋₅ cicloalquilo y C₅ cicloalquenilo, cada uno de los cuales puede estar sustituido opcionalmente con uno o más sustituyentes R⁷, idénticos o diferentes; R⁵ está seleccionado del grupo que consiste en C₁₋₅ alquilo opcionalmente sustituido con uno o más sustituyentes R⁸ idénticos o diferentes, C₂₋₅ alquenilo, C₂₋₅ alquinilo, C₃₋₆ cicloalquilo opcionalmente sustituido con uno o más sustituyentes R⁸, idénticos o diferentes, fenilo opcionalmente sustituido con uno o más sustituyentes R⁹, idénticos o diferentes y bencilo opcionalmente sustituido con uno o más sustituyentes R⁹, idénticos o diferentes; R⁶ está seleccionado del grupo que consiste en H, deuterio, C₁₋₅ alquilo y C₃₋₅ cicloalquilo; R⁷ está independientemente seleccionado del grupo que consiste en deuterio, tritio, F, Cl, Br, I, CN, isocianuro, C₃₋₅ cicloalquilo opcionalmente sustituido con uno o más sustituyentes R⁸, idénticos o diferentes, O-C₁₋₃ alquilo opcionalmente sustituido con uno o más sustituyentes R⁸, idénticos o diferentes, S-C₁₋₃ alquilo opcionalmente sustituido con uno o más sustituyentes R⁸, idénticos o diferentes, CH₂-O-C₁₋₃ alquilo opcionalmente sustituido con uno o más sustituyentes R⁸, idénticos o diferentes, y CH₂-S-C₁₋₃ alquilo opcionalmente sustituido con uno o más sustituyentes R⁸, idénticos o diferentes; R⁸ está independientemente seleccionado del grupo que consiste en deuterio y F; R⁹ está independientemente seleccionado del grupo que consiste en deuterio, metoxi, nitro, ciano, Cl, Br, I y F; y n es un entero 0, 1, 2 ó 3.
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP19181262 | 2019-06-19 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AR119198A1 true AR119198A1 (es) | 2021-12-01 |
Family
ID=66999603
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ARP200101735A AR119198A1 (es) | 2019-06-19 | 2020-06-19 | Proceso para la preparación de inhibidores del canal de cloruro cic-1 |
Country Status (18)
| Country | Link |
|---|---|
| US (1) | US12221425B2 (es) |
| EP (1) | EP3986878B1 (es) |
| JP (1) | JP7595945B2 (es) |
| KR (1) | KR102900834B1 (es) |
| CN (1) | CN113993852B (es) |
| AR (1) | AR119198A1 (es) |
| AU (1) | AU2020298092B2 (es) |
| BR (1) | BR112021025588A2 (es) |
| CA (1) | CA3137672A1 (es) |
| ES (1) | ES3000437T3 (es) |
| HU (1) | HUE069104T2 (es) |
| IL (1) | IL287901B2 (es) |
| MX (1) | MX2021013507A (es) |
| PL (1) | PL3986878T3 (es) |
| SG (1) | SG11202111122RA (es) |
| TW (1) | TWI849152B (es) |
| WO (1) | WO2020254554A1 (es) |
| ZA (1) | ZA202107653B (es) |
Families Citing this family (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR20250077496A (ko) | 2022-09-30 | 2025-05-30 | 엔엠디 파마 에이/에스 | 중증 근무력증을 치료하기 위한 조성물 및 방법 |
| WO2024180199A1 (en) | 2023-03-02 | 2024-09-06 | Nmd Pharma A/S | Compositions and methods for treating charcot–marie–tooth disease |
| IL321850A (en) | 2023-03-02 | 2025-08-01 | Nmd Pharma As | Preparations and methods for treating spinal muscular atrophy |
| AU2024311729A1 (en) | 2023-06-20 | 2025-11-27 | Nmd Pharma A/S | Clc-1 inhibitors for use in the treatment of multiple sclerosis and neuromuscular diseases |
Family Cites Families (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| SE0301010D0 (sv) * | 2003-04-07 | 2003-04-07 | Astrazeneca Ab | Novel compounds |
| GB0422057D0 (en) * | 2004-10-05 | 2004-11-03 | Astrazeneca Ab | Novel compounds |
| GB0524428D0 (en) * | 2005-11-30 | 2006-01-11 | 7Tm Pharma As | Medicinal use of receptor ligands |
| CA2713550C (en) * | 2008-02-05 | 2016-06-14 | Sanofi-Aventis | Triazolopyridazines as par1 inhibitors, production thereof, and use as medicaments |
| CN104169276A (zh) * | 2012-02-03 | 2014-11-26 | 佐蒂斯有限责任公司 | 作为抗寄生物剂的手性异噁唑啉氮杂环丁烷衍生物的制备方法 |
| RU2745065C2 (ru) | 2015-06-15 | 2021-03-18 | ЭнЭмДи ФАРМА A/C | Соединения для применения для лечения нервно-мышечных расстройств |
| TWI780281B (zh) * | 2017-12-14 | 2022-10-11 | 丹麥商Ｎｍｄ藥品公司 | 用於治療神經肌肉病症的化合物 |
| US10385028B2 (en) * | 2017-12-14 | 2019-08-20 | Nmd Pharma A/S | Compounds for the treatment of neuromuscular disorders |
-
2020
- 2020-06-19 SG SG11202111122RA patent/SG11202111122RA/en unknown
- 2020-06-19 JP JP2021569300A patent/JP7595945B2/ja active Active
- 2020-06-19 CN CN202080043796.2A patent/CN113993852B/zh active Active
- 2020-06-19 IL IL287901A patent/IL287901B2/en unknown
- 2020-06-19 ES ES20734157T patent/ES3000437T3/es active Active
- 2020-06-19 PL PL20734157.9T patent/PL3986878T3/pl unknown
- 2020-06-19 AU AU2020298092A patent/AU2020298092B2/en active Active
- 2020-06-19 EP EP20734157.9A patent/EP3986878B1/en active Active
- 2020-06-19 KR KR1020217037880A patent/KR102900834B1/ko active Active
- 2020-06-19 HU HUE20734157A patent/HUE069104T2/hu unknown
- 2020-06-19 MX MX2021013507A patent/MX2021013507A/es unknown
- 2020-06-19 US US17/619,312 patent/US12221425B2/en active Active
- 2020-06-19 WO PCT/EP2020/067065 patent/WO2020254554A1/en not_active Ceased
- 2020-06-19 CA CA3137672A patent/CA3137672A1/en active Pending
- 2020-06-19 TW TW109120910A patent/TWI849152B/zh active
- 2020-06-19 AR ARP200101735A patent/AR119198A1/es unknown
- 2020-06-19 BR BR112021025588A patent/BR112021025588A2/pt unknown
-
2021
- 2021-10-11 ZA ZA2021/07653A patent/ZA202107653B/en unknown
Also Published As
| Publication number | Publication date |
|---|---|
| MX2021013507A (es) | 2021-12-10 |
| TWI849152B (zh) | 2024-07-21 |
| US20220298124A1 (en) | 2022-09-22 |
| ES3000437T3 (en) | 2025-02-28 |
| EP3986878C0 (en) | 2024-09-25 |
| AU2020298092A1 (en) | 2021-11-18 |
| CN113993852B (zh) | 2024-12-17 |
| PL3986878T3 (pl) | 2025-01-20 |
| CA3137672A1 (en) | 2020-12-24 |
| BR112021025588A2 (pt) | 2022-02-01 |
| AU2020298092A8 (en) | 2025-04-24 |
| AU2020298092B2 (en) | 2025-09-25 |
| IL287901B2 (en) | 2025-02-01 |
| EP3986878A1 (en) | 2022-04-27 |
| HUE069104T2 (hu) | 2025-02-28 |
| EP3986878B1 (en) | 2024-09-25 |
| ZA202107653B (en) | 2023-05-31 |
| WO2020254554A1 (en) | 2020-12-24 |
| IL287901A (en) | 2022-01-01 |
| JP2022537493A (ja) | 2022-08-26 |
| IL287901B1 (en) | 2024-10-01 |
| TW202115003A (zh) | 2021-04-16 |
| JP7595945B2 (ja) | 2024-12-09 |
| SG11202111122RA (en) | 2021-11-29 |
| CN113993852A (zh) | 2022-01-28 |
| US12221425B2 (en) | 2025-02-11 |
| KR20220022895A (ko) | 2022-02-28 |
| KR102900834B1 (ko) | 2025-12-16 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AR119198A1 (es) | Proceso para la preparación de inhibidores del canal de cloruro cic-1 | |
| PE20190329A1 (es) | Compuestos moduladores de fxr (nr1h4) | |
| CO2021000808A2 (es) | Agente profiláctico o terapéutico para atrofia muscular espinal | |
| PE20190656A1 (es) | Compuestos de tiazolo-piridina sustituida como inhibidores de malt1 | |
| CO6300865A2 (es) | Derivados polisustituidos de 2 aril-6-fenil-imidazo[1,2-a]piridinas su preparacion y su aplicacion en terapeutica | |
| AR093579A1 (es) | Inhibidores de bmi-1 de pirimidina inversa sustituida | |
| ES2639757T3 (es) | Síntesis de 2-(1H-indazol-6-il)espiro[ciclopropan-1,3'-indolin]-2'-onas quirales | |
| CO6290657A2 (es) | Derivados polisustituidos de 2-aril-6-fenil-imidazo[1,2-alfa]piridinas su preparacion y su aplicacion en terapeutica | |
| ES2308299T3 (es) | Tiadiazoles como ligandos de receptores de cxc-y cc-quimioquinas. | |
| AR113929A1 (es) | Compuestos heterocíclicos | |
| AR103742A1 (es) | Derivados de trifluorometilpropanamida | |
| AR122092A1 (es) | Inhibidores de diacilglicerol o-aciltransferasa 2 | |
| AR108387A1 (es) | Compuestos de tipo tetrahidropirimidodiazepina y dihidropiridodiazepina para tratar el dolor y afecciones relacionadas con el dolor | |
| MY162998A (en) | Ethynyl derivatives | |
| EP4464334A3 (en) | Use of compounds for treating hk2-expressing cancers | |
| AR061973A1 (es) | Compuesto de 2-arilindol sustituido en la posicion 5, composicion farmaceutica que lo comprende, compuestos intermedios y procedimiento para la preparacion de los mismos | |
| AR130984A1 (es) | Compuestos novedosos | |
| AR116400A1 (es) | Compuesto de imidazopiridinona | |
| AR100776A1 (es) | Compuestos herbicidas | |
| AR117388A1 (es) | Compuestos herbicidas | |
| AR094944A1 (es) | Compuestos sustituidos con halógeno | |
| AR130709A1 (es) | Compuesto de ciclopentano | |
| AR119341A1 (es) | Profármacos de moduladores del receptor de nmda | |
| AR069028A1 (es) | Derivados de 1,2,4-triazol pirrolidina fusionados como moduladores de mglur5 | |
| AR106475A1 (es) | Derivados de piridina o de pirimidina |